Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bronte Naples

Nurse Practitioner, Family Chattanooga, TN Nurse Practitioner

NPI 1992291926 CMS profile 10990903

1000 E 3Rd St Ste 300, Chattanooga, TN 37403

Open in the dashboard

General payments

$26,362

217 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bronte Naples of Chattanooga, TN is reported in the CMS Open Payments database as having received $26,362 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,886 52
2024 General $8,935 41
2023 General $5,140 38
2022 General $1,097 37
2021 General $1,306 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bronte Naples
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Bronte Naples were reported at $9,886. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Bronte Naples Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,306 $124 $35–$379 $132
2022 $1,097 $141 $44–$430 $149
2023 $5,140 $154 $49–$476 $160
2024 $8,935 $165 $51–$504 $164
2025 $9,886 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $23,959 148 payments
  2. AbbVie, Inc. $685 18 payments
  3. ViiV Healthcare Company $305 24 payments
  4. Novo Nordisk Inc $288 6 payments
  5. AstraZeneca Pharmaceuticals LP $281 4 payments
  6. Janssen Products, LP $252 3 payments
  7. Boston Scientific Corporation $131 1 payment
  8. Janssen Pharmaceuticals, Inc $124 2 payments
  9. Mylan Specialty L.P. $124 1 payment
  10. Janssen Biotech, Inc. $69 3 payments
  11. Other $145 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,745 16 payments
  2. Food and Beverage $5,106 184 payments
  3. Travel and Lodging $3,259 14 payments
  4. Education $252 3 payments
Products named General payments · program years 2021–2025
  1. Biktarvy $16,599 40 payments
  2. SYMTUZA $321 6 payments
  3. UBRELVY $279 8 payments
  4. VRAYLAR $272 3 payments
  5. Epclusa $231 2 payments
  6. RYBELSUS $214 5 payments
  7. CABENUVA $149 8 payments
  8. MAVYRET $133 7 payments
  9. WATCHMAN Access System $131 1 payment
  10. Yeztugo $125 1 payment
  11. Other $874 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,382

Median for Nurse Practitioner: 389

Drug cost

$2,491,536

Median for Nurse Practitioner: $21,885

Branded share of claims

64.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 346 $1,384,044
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 62 $203,602
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 44 $188,801
Descovy Emtricitabine/Tenofov Alafenam Brand 92 $188,033
Tivicay Dolutegravir Sodium Brand 71 $147,015
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 27 $126,535
Prezcobix Darunavir/Cobicistat Brand 39 $94,315
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 26 $90,950
Dovato Dolutegravir Sodium/Lamivudine Brand 14 $39,225
Mounjaro Tirzepatide Brand 12 $11,759

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Biktarvy
  • Gilead Sciences, Inc. $7,248
$7,248 346 —
Descovy
  • Gilead Sciences, Inc. $96
$96 92 —
DOVATO
  • ViiV Healthcare Company $16
$16 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record